Concurrent Changes in Plasma Phosphorylated Tau 217, Tau PET, and Cognition in Preclinical Alzheimer Disease

Are plasma phosphorylated tau 217 (p-tau217) and tau positron emission tomography (PET) suitable biomarkers to detect disease modification in preclinical Alzheimer disease clinical trials?In this diagnostic/prognostic study, changes in tau PET uptake in frontoparietal regions were strongly associated with concurrent changes in cognition. Changes in plasma p-tau217 were more modestly associated with concurrent cognitive changes.These findings highlight the value of tau PET for real-time tracking of disease progression to enhance detection of disease-modifying effects in preclinical Alzheimer disease trials.

Corresponding Author: Philip S. Insel, PhD, Department of Psychiatry and Behavioral Sciences, University of California, San Francisco, 401 Parnassus Ave, San Francisco, CA 94121 (philip.insel@ucsf.edu).

Link to the article in your story

We encourage you to link out to this article in your story using the link below. It includes an access token that will give free access to the article for your readers up to one year after publication. (The link will be live after the article publishes and embargo is lifted.)

Please see the article for additional information, including full author list, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

Need more information? Contact us.